Who are CG5503 IR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): KPI-121 Ophthalmic Suspension, KPS-0373, High dose, TV-44749.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cg5503-ir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

CG5503 IR — Competitive Intelligence Brief

CG5503 IR (CG5503 IR) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPV1 antagonist. Area: Pain Management.

phase 3 TRPV1 antagonist TRPV1 (Transient Receptor Potential Vanilloid 1) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

CG5503 IR (CG5503 IR) — Grünenthal GmbH. CG5503 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CG5503 IR TARGET	CG5503 IR	Grünenthal GmbH	phase 3	TRPV1 antagonist	TRPV1 (Transient Receptor Potential Vanilloid 1)
KPI-121 Ophthalmic Suspension	KPI-121 Ophthalmic Suspension	Kala Pharmaceuticals, Inc.	phase 3	TRPV1 antagonist / Topical anti-inflammatory	TRPV1 (Transient Receptor Potential Vanilloid 1)
KPS-0373, High dose	KPS-0373, High dose	Kissei Pharmaceutical Co., Ltd.	phase 3	TRPV1 antagonist	TRPV1
TV-44749	TV-44749	Teva Branded Pharmaceutical Products R&D LLC	phase 3	TRPV1 antagonist	TRPV1 (Transient Receptor Potential Vanilloid 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPV1 antagonist class)

Allergan · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Kissei Pharmaceutical Co., Ltd. · 1 drug in this class
Teva Branded Pharmaceutical Products R&D LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CG5503 IR — Competitive Intelligence Brief. https://druglandscape.com/ci/cg5503-ir. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab